Surrozen (NASDAQ:SRZN – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday, Wall Street Zen reports.
Several other research firms also recently commented on SRZN. Cantor Fitzgerald lifted their price objective on shares of Surrozen from $40.00 to $62.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 10th. HC Wainwright reissued a “buy” rating and issued a $54.00 target price (up from $44.00) on shares of Surrozen in a research report on Friday, September 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research report on Thursday, October 15th. William Blair began coverage on Surrozen in a research note on Thursday, August 20th. They issued an “outperform” rating and a $51.00 target price for the company. Finally, Zacks Research raised Surrozen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 28th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $61.75.
Get Our Latest Stock Report on Surrozen
Surrozen Stock Performance
Shares of SRZN stock opened at $31.61 on Friday. Surrozen has a fifty-two week low of $12.31 and a fifty-two week high of $37.83. The firm has a market capitalization of $602.49 million, a price-to-earnings ratio of -0.73 and a beta of 0.51. The stock’s 50-day simple moving average is $25.90 and its 200-day simple moving average is $25.52.
Surrozen (NASDAQ:SRZN – Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported ($11.02) EPS for the quarter, missing the consensus estimate of ($1.10) by ($9.92). As a group, equities analysts forecast that Surrozen will post -10.89 earnings per share for the current year.
Institutional Investors Weigh In On Surrozen
A number of hedge funds and other institutional investors have recently made changes to their positions in SRZN. Perceptive Advisors LLC purchased a new position in Surrozen in the first quarter valued at $6,682,000. Jump Financial LLC purchased a new stake in shares of Surrozen during the 3rd quarter worth about $1,966,000. Renaissance Technologies LLC boosted its stake in shares of Surrozen by 117.1% during the 1st quarter. Renaissance Technologies LLC now owns 49,126 shares of the company’s stock worth $1,431,000 after acquiring an additional 26,500 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Surrozen during the 2nd quarter worth about $399,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Surrozen during the 1st quarter valued at about $350,000. Institutional investors and hedge funds own 66.57% of the company’s stock.
Key Surrozen News
Here’s some of the latest news about SRZN:
- Positive Sentiment: HC Wainwright maintained its Buy rating and $54 price target, signaling potential upside in the analyst’s view despite reduced earnings forecasts. HC Wainwright estimates and rating
- Negative Sentiment: Surrozen priced an underwritten offering of 1,894,540 common shares at $31.67 each, raising about $60 million before expenses. The new shares dilute existing shareholders and could weigh on the stock, while providing additional funding for the company. Surrozen announces offering pricing
- Negative Sentiment: HC Wainwright lowered its projected earnings per share across several future years, including estimates of losses of $12.01 for 2026 and $5.19 for 2027. The lower forecasts underscore continued expected losses, despite the firm’s Buy rating. HC Wainwright earnings estimates
Surrozen Company Profile
Surrozen, Inc. is a biotechnology company developing antibody-based medicines designed to activate the Wnt signaling pathway, which plays a role in tissue growth and repair. The company uses its proprietary platform to develop therapies intended to stimulate regeneration in specific tissues while limiting effects elsewhere in the body. Surrozen’s research has included candidates aimed at liver disease and inflammatory bowel disease, including SZN-043 and SZN-1326. Its work focuses on advancing potential treatments through research and clinical development; the company’s products are investigational and are not approved medicines.
Featured Articles
- Five stocks we like better than Surrozen
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with MarketBeat.com's FREE daily email newsletter.
